創薬技術市場規模、シェア、動向、2030年までの世界予測

創薬技術市場は、2025年の305億8,000万米ドルから2030年には515億1,000万米ドルに達し、予測期間中は年平均成長率（CAGR）11.0%で成長すると予測されています。市場の成長を牽引しているのは、高度なスクリーニングプラットフォームの導入拡大と、3D細胞培養、オルガノイド、臓器チップモデルへの移行です。これらの技術は、疾患の関連性を高め、予測精度を向上させ、より効率的で信頼性の高い創薬プロセスをサポートします。さらに、標的治療や精密治療への移行も需要を押し上げています。しかしながら、高い技術コスト、複雑なワークフロー、そして熟練した専門家の必要性が、依然として市場の成長を抑制しています。

調査対象範囲

本調査レポートでは、創薬技術市場を製品（試薬・消耗品、機器、バイオインフォマティクスツール・ソフトウェア）、技術（ハイスループットスクリーニング技術、次世代シーケンシング、ポリメラーゼ連鎖反応、インシリコ/AIベースの創薬技術、X線結晶構造解析、クロマトグラフィー、質量分析、その他の技術）、プロセス（標的同定、標的検証、ヒット・トゥ・リード同定、リード最適化、候補化合物検証）、治療領域（腫瘍学、感染症、心血管疾患、神経疾患、内分泌・代謝性疾患、自己免疫疾患、その他の治療領域）、エンドユーザー（製薬企業・バイオテクノロジー企業、学術研究機関、受託研究機関（CRO）、その他のエンドユーザー）、地域（北米、欧州、アジア太平洋、ラテンアメリカ、中東、アフリカ）に分類しています。

本レポートは、創薬技術市場の成長に影響を与える主要な要因（促進要因、制約要因、課題、機会など）に関する詳細な情報を網羅しています。主要業界プレーヤーの包括的な分析により、各社の事業概要、製品ポートフォリオ、主要戦略、新製品の発売、買収、そして創薬技術市場に関連する最近の動向に関する洞察を提供しています。また、本レポートには、創薬技術業界のエコシステムにおける新興スタートアップ企業の競合分析も含まれています。

レポート購入の主なメリット

本レポートは、市場全体とそのサブセグメントの収益予測を提供することで、市場リーダー企業と新規参入企業を支援します。また、ステークホルダーが競争環境をより深く理解し、ビジネスを効果的にポジショニングし、適切な市場開拓戦略を策定するための洞察を深めるのに役立ちます。本レポートは、ステークホルダーが市場の動向を把握し、主要な市場牽引要因、制約要因、機会、課題に関する情報を提供することを可能にします。

本レポートでは、以下の点について洞察を提供しています。

• 市場の成長に影響を与える主要な推進要因（高度なスクリーニングプラットフォームの導入増加、生物製剤および高度な治療法への移行、従来の2次元培養から3次元モデルへの移行、アッセイの小型化および自動化における技術革新）、制約要因（機器、自動化、データインフラへの多額の先行投資、熟練した人材の不足）、機会（in silicoベースの発見に対する需要の高まり、および専門的なADME/毒性試験のニーズ増加）、および課題（アッセイの再現性と標準化の問題）の分析
• 製品開発／イノベーション：新発売製品に関する詳細な洞察と創薬技術市場の技術評価
• 市場開発：収益性の高い市場に関する包括的な情報と、様々な地域における市場分析
• 市場多様化：新製品、未開拓地域、最近の開発状況、創薬技術市場への投資に関する網羅的な情報
• 競合評価：Thermo Fisher Scientific Inc.（米国）、Danaher Corporation（米国）、Agilent Technologies, Inc.（米国）、Illumina, Inc.（米国）、Revvity（米国）など、創薬技術市場向け製品を提供する主要企業の市場シェア、成長戦略、製品提供に関する詳細な評価。その他、Polaris Genomics（米国）、BICO（スウェーデン）、Creative Bioarray（米国）、Sphere Bio（英国）、GenScript（英国）、Schrödinger, Inc.（米国）、LECO Corporation（米国）など、創薬技術市場における主要企業。

Report Description

The drug discovery technologies market is expected to reach USD 51.51 billion in 2030 from USD 30.58 billion in 2025, at a CAGR of 11.0% during the forecast period. The market is driven by the increasing adoption of advanced screening platforms and the shift toward 3D cell cultures, organoids, and organ-on-a-chip models. These technologies improve disease relevance, enhance predictive accuracy, and support more efficient and reliable drug discovery processes. Furthermore, the shift towards targeted and precision therapies further boosts demand. However, high technology costs, complex workflows, and the need for skilled professionals continue to limit market growth.

The in-silico/AI-based drug discovery segment is expected to grow at the highest CAGR during the forecast period.

The in silico/AI-based drug discovery technology segment is growing at the highest CAGR in the drug discovery technologies market due to its ability to shorten discovery timelines, reduce costs, and improve success rates. These technologies use computational modeling, machine learning, and data analytics to rapidly identify and optimize drug candidates. By analyzing large biological and chemical datasets, AI-based platforms enable accurate target identification, lead screening, and toxicity prediction at early stages. This reduces reliance on trial-and-error laboratory methods and minimizes late-stage failures. Their scalability, speed, and ability to support precision medicine make in silico and AI-based technologies essential tools for pharmaceutical and biotechnology companies, driving strong adoption across the market.

The oncology segment holds the largest share of the market.

The oncology segment accounts for the largest share of the Drug Discovery Technologies Market. This growth is driven by the increasing prevalence of cancer worldwide and the rising focus on developing targeted and personalized therapies. Advanced screening platforms, high-throughput assays, and cell-based models are widely used to identify potential drug candidates, validate targets, and optimize leads. Strong investments in cancer research, expanding clinical pipelines, and growing collaboration between pharmaceutical companies and research institutes further support the adoption of these technologies. Improved drug development efficiency and the demand for more effective cancer treatments continue to drive growth in this segment globally.

The US is expected to grow at the highest CAGR during the forecast period.

The US is experiencing the highest growth in the drug discovery technologies market due to several factors. A strong presence of leading pharmaceutical and biotech companies, advanced research infrastructure, and a large number of ongoing oncology programs are key drivers. Increasing adoption of high-throughput screening, 3D cell models, and organ-on-a-chip platforms in cancer research is fueling demand. Supportive regulations, substantial public and private funding for biomedical research, and a focus on precision medicine further contribute to market expansion. Widespread use of advanced discovery technologies and robust collaborations between industry and research institutes enhance innovation, ensuring high-quality outputs and reinforcing North America’s leading position globally.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side – 70% and Demand Side– 30%
• By Designation: Managers – 45%, CXOs and Directors – 30%, and Executives – 25%
• By Region: North America – 40%, Europe – 25%, Asia Pacific – 25%, Latin America – 5%, the Middle East & Africa – 5%

Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Agilent Technologies, Inc. (US), Illumina, Inc. (US), Revvity (US), F. Hoffmann-La Roche Ltd (Switzerland), Bruker (US), QIAGEN (Germany), Bio-Rad Laboratories, Inc. (US), Tecan Trading AG (Switzerland), Takara Bio Inc. (Japan), Corning Incorporated (US), Hamilton Company (US), PacBio (US), Oxford Nanopore Technologies plc (UK), Promega Corporation (US), Waters Corporation (US), Merck KGAA (Germany), Sartorius AG (Germany), BD (US), Eppendorf SE (Germany), Shimadzu Corporation (Japan), Aurora Biomed Inc. (Canada), Standard BioTools (US), Jeol Ltd. (Japan), Gilson Incorporated (US), BIOMÉRIEUX (France), Greiner AG (Austria), BGI Group (China), Porvair (UK), Polaris Genomics (US), BICO (Sweden), Creative Bioarray (US), Sphere Bio (UK), GenScript (UK), Schrödinger, Inc. (US), LECO Corporation (US), TransGen Biotech Co., Ltd. (China), BMG LABTECH (Germany), NanoTemper Technologies (Germany), MGI Tech Co., Ltd. (China), Araceli Biosciences (US), Sphere Bio (US), BioSolvelT GmbH (Germany), and Evosep (Denmark)  are some of the key companies offering drug discovery technologies products.

Research Coverage

This research report categorizes the drug discovery technologies market by product (reagents & consumables, instruments, bioinformatics tools & software), technology (high-throughput screening technologies, next-generation sequencing, polymerase chain reaction, in-silico/AI-based drug discovery technologies, X-ray crystallography, chromatography, mass spectrometry, other technologies), process (target identification, target validation, hit-to-lead identification, lead optimization, candidate validation), therapeutic area (oncology, infectious diseases, cardiovascular diseases, neurological diseases, endocrine & metabolic diseases, autoimmune disorders, other therapeutic areas), end user (pharmaceutical & biotechnology companies, academic & research institutes, contract research organizations (CROs), other end users), and region (North America, Europe, Asia Pacific, Latin America, Middle East, And Africa).

The report’s scope encompasses detailed information about the primary factors, including drivers, restraints, challenges, and opportunities, that influence the growth of the drug discovery technologies market. A comprehensive analysis of key industry players has been performed to provide insights into their business overview, product portfolio, key strategies, new product launches, acquisitions, and recent developments related to the drug discovery technologies market. This report also includes a competitive analysis of emerging startups in the drug discovery technologies industry ecosystem.

Key Benefits of Buying the Report

The report will assist market leaders and new entrants by providing revenue estimates for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their businesses effectively and develop suitable go-to-market strategies. This report will enable stakeholders to grasp the market’s pulse and offer information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (increasing adoption of advanced screening platforms, shift toward biologics and advanced therapeutic modalities, transition from conventional two-dimensional cultures to three-dimension models, technological innovations in assay miniaturization and automation), restraints (high up-front investment in instruments, automation, and data infrastructure and shortage of skilled personnel), opportunities (growing demand for in-silico based discovery and increasing need for specialized ADME/Toxicology testing), and challenges (assay reproducibility and standardization issues) influencing the market growth
• Product Development/Innovation: Detailed insights into newly launched products and technological assessment of the drug discovery technologies market
• Market Development: Comprehensive information about lucrative markets and analysis of the market across varied regions
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the drug discovery technologies market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players, including Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Agilent Technologies, Inc. (US), Illumina, Inc. (US), Revvity (US), among others, offering products for the drug discovery technologies market. Other companies include Polaris Genomics (US), BICO (Sweden), Creative Bioarray (US), Sphere Bio (UK), GenScript (UK), Schrödinger, Inc. (US), LECO Corporation (US), among others, for the drug discovery technologies market.

Table of Contents

1 INTRODUCTION 42
1.1 STUDY OBJECTIVES 42
1.2 MARKET DEFINITION 42
1.3 STUDY SCOPE 42
1.3.1 MARKET SEGMENTATION AND REGIONS COVERED 43
1.3.2 INCLUSIONS AND EXCLUSIONS 44
1.3.3 YEARS CONSIDERED 44
1.4 CURRENCY CONSIDERED 45
1.5 STAKEHOLDERS 45
1.6 SUMMARY OF CHANGES 45
2 EXECUTIVE SUMMARY 47
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS 47
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 48
2.3 DISRUPTIVE TRENDS IN DRUG DISCOVERY TECHNOLOGIES MARKET 49
2.4 HIGH-GROWTH SEGMENTS 50
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 51
3 PREMIUM INSIGHTS 53
3.1 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT 53
3.2 DRUG DISCOVERY TECHNOLOGIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 54
3.3 DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2025 VS. 2030 (%) 55
4 MARKET OVERVIEW 56
4.1 INTRODUCTION 56
4.2 MARKET DYNAMICS 56
4.2.1 DRIVERS 57
4.2.1.1 Increasing adoption of advanced screening platforms 57
4.2.1.2 Shift toward biologics and advanced therapeutic modalities 58
4.2.1.3 Transition from conventional two-dimensional cultures to three-dimensional models 58
4.2.1.4 Technological innovations in assay miniaturization and automation 59
4.2.2 RESTRAINTS 59
4.2.2.1 High up-front investment in instruments, automation,
and data infrastructure 59
4.2.2.2 Shortage of skilled personnel 60
4.2.3 OPPORTUNITIES 60
4.2.3.1 Growing demand for in-silico-based discovery 60
4.2.3.2 Increasing need for specialized ADME/Toxicology testing 60
4.2.4 CHALLENGES 61
4.2.4.1 Assay reproducibility and standardization issues 61
4.3 UNMET NEEDS AND WHITE SPACES 61
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 62
4.5 STRATEGIC MOVIES BY TIER-1/2/3 PLAYERS 62
5 INDUSTRY TRENDS 64
5.1 PORTER’S FIVE FORCES ANALYSIS 64
5.1.1 INTENSITY OF COMPETITIVE RIVALRY 65
5.1.2 BARGAINING POWER OF SUPPLIERS 65
5.1.3 BARGAINING POWER OF BUYERS 66
5.1.4 THREAT OF SUBSTITUTES 66
5.1.5 THREAT OF NEW ENTRANTS 66
5.2 MACROECONOMIC OUTLOOK 66
5.2.1 INTRODUCTION 66
5.2.2 GDP TRENDS AND FORECAST 66
5.2.3 R&D TRENDS IN GLOBAL HEALTHCARE INDUSTRY 67
5.2.4 R&D TRENDS IN GLOBAL PHARMA INDUSTRY 67
5.3 VALUE CHAIN ANALYSIS 68
5.4 ECOSYSTEM ANALYSIS 69
5.5 PRICING ANALYSIS 71
5.5.1 AVERAGE SELLING PRICE OF END USERS, BY KEY PLAYER, 2024 71
5.5.2 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER,
2022–2024 71
5.5.2.1 Average selling price of instruments, by key player, 2024 72
5.5.2.2 Average selling price of consumables, by key player, 2024 73
5.5.3 AVERAGE SELLING PRICE TREND, BY TECHNOLOGY, 2022−2024 73
5.5.4 AVERAGE SELLING PRICE TREND, BY REGION, 2022–2024 74
5.6 TRADE ANALYSIS 75
5.6.1 IMPORT SCENARIO FOR HS CODE 3822.00 76
5.6.2 EXPORT SCENARIO FOR HS CODE 3822.00 76
5.6.3 IMPORT SCENARIO FOR HS CODE 9027.00 77
5.6.4 EXPORT SCENARIO FOR HS CODE 9027.00 78
5.7 KEY CONFERENCES AND EVENTS, 2025–2026 79
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 80
5.9 INVESTMENT AND FUNDING SCENARIO 80
5.10 CASE STUDY ANALYSIS 81
5.10.1 AI-DESIGNED IPF DRUG CANDIDATE ADVANCES IN CLINICAL DEVELOPMENT 81
5.10.2 INDUSTRY CONSORTIUM POOLS DATA TO IMPROVE AI-DRIVEN SMALL MOLECULE DISCOVERY 82
5.10.3 NEW AI FRAMEWORK FROM IIT MADRAS AND OHIO STATE STREAMLINES MOLECULAR DESIGN 82

5.11 IMPACT OF 2025 US TARIFF ON DRUG DISCOVERY TECHNOLOGIES MARKET 82
5.11.1 INTRODUCTION 82
5.11.2 KEY TARIFF RATES 82
5.11.3 PRICE IMPACT ANALYSIS 86
5.11.4 KEY IMPACT ON COUNTRIES/REGIONS 86
5.11.4.1 US 86
5.11.4.2 Europe 87
5.11.4.3 Asia Pacific 87
5.11.5 END-USE INDUSTRY IMPACT 87
5.11.5.1 Pharmaceutical and Biotechnology Companies 87
5.11.5.2 Academic and Research Institutes 88
5.11.5.3 Contract Research Organizations (CROs) 88
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 89
6.1 KEY EMERGING TECHNOLOGIES 89
6.1.1 HIGH-THROUGHPUT SCREENING (HTS) & AUTOMATION 89
6.1.2 AUTOMATED LIQUID HANDLING 89
6.2 ADJACENT TECHNOLOGIES 90
6.2.1 AI/ML-ENABLED & IN SILICO DISCOVERY PLATFORMS 90
6.2.2 DISCOVERY INFORMATICS & LAB DIGITALIZATION 90
6.3 TECHNOLOGY/PRODUCT ROADMAP 91
6.4 PATENT ANALYSIS 91
6.4.1 METHODOLOGY 91
6.4.2 NUMBER OF PATENTS FILED 91
6.4.3 LIST OF KEY PATENTS 93
6.5 FUTURE APPLICATIONS 94
6.6 IMPACT OF AI/GEN AI ON DRUG DISCOVERY TECHNOLOGIES MARKET 94
6.6.1 TOP USE CASES AND MARKET POTENTIAL 95
6.6.2 BEST PRACTICES IN AI-ENABLED DRUG DISCOVERY WORKFLOWS 96
6.6.3 CASE STUDIES OF AI IMPLEMENTATION IN DRUG DISCOVERY
TECHNOLOGIES MARKET 96
6.6.4 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS 96
6.6.5 CLIENTS’ READINESS TO ADOPT GENERATIVE MOLECULAR DESIGN
IN DRUG DISCOVERY TECHNOLOGIES MARKET 97
7 SUSTAINABILITY AND REGULATORY LANDSCAPE 98
7.1 REGIONAL REGULATIONS AND COMPLIANCE 98
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98
7.1.2 INDUSTRY STANDARDS 100
7.1.2.1 North America 101
7.1.2.1.1 US 101
7.1.2.1.2 Canada 101
7.1.2.2 Europe 101
7.1.2.2.1 UK 102
7.1.2.3 Asia Pacific 102
7.1.2.3.1 China 102
7.1.2.3.2 Japan 103
7.1.2.3.3 India 103
7.1.2.3.4 South Korea 103
7.1.2.3.5 Australia 104
7.1.2.3.6 Rest of Asia Pacific 104
7.2 SUSTAINABILITY INITIATIVES 104
7.3 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES 105
7.4 CERTIFICATIONS, LABELING, ECO-STANDARDS 105
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOUR 107
8.1 DECISION-MAKING PROCESS 107
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 107
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 107
8.2.2 KEY BUYING CRITERIA, BY END USER 108
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 109
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 109
9 DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT 111
9.1 INTRODUCTION 112
9.2 REAGENTS & CONSUMABLES 112
9.2.1 INNOVATIONS IN ASSAY CHEMISTRY AND SUPPLY CHAIN RESILIENCE TO PROMOTE GROWTH 112
9.3 INSTRUMENTS 116
9.3.1 HIGH-PERFORMANCE ANALYTICAL ATTRIBUTES AND AUTOMATION TO DRIVE MARKET 116
9.4 BIOINFORMATICS TOOLS & SOFTWARE 119
9.4.1 AI RISING ADOPTION OF AI AND MACHINE LEARNING FOR PREDICTIVE MODELING TO FUEL MARKET 119
10 DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY 123
10.1 INTRODUCTION 124
10.2 HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES 124
10.2.1 AUTOMATED LIQUID HANDLING 128
10.2.1.1 Increasing focus on precision, integration, and productivity to drive market 128
10.2.2 MICROPLATE-BASED HTS 132
10.2.2.1 Rising investments in pharmaceutical and biotechnology R&D
to fuel market 132
10.2.3 LAB-ON-A CHIP 135
10.2.3.1 Increasing demand for more predictive preclinical models to boost market 135
10.2.4 LABEL-FREE TECHNOLOGY 139
10.2.4.1 Real-time, label-free interaction to accelerate segment growth 139
10.3 NEXT-GENERATION SEQUENCING 142
10.3.1 EXPANDED INTEGRATION OF ADVANCED NGS TECHNOLOGIES TO DRIVE MARKET 142
10.4 POLYMERASE CHAIN REACTION 146
10.4.1 ENHANCED POLYMERASE CHAIN REACTION INNOVATION AND AUTOMATION TO DRIVE MARKET 146
10.5 IN-SILICO/ AI-BASED DRUG DISCOVERY TECHNOLOGIES 149
10.5.1 COMPUTATIONAL INTELLIGENCE AND COLLABORATIVE AI INNOVATIONS TO PROPEL MARKET 149
10.6 X-RAY CRYSTALLOGRAPHY 152
10.6.1 ADVANCED INSTRUMENTATION AND INNOVATIVE X-RAY TECHNIQUES TO BOOST MARKET 152
10.7 CHROMATOGRAPHY 156
10.7.1 REGULATORY PRESSURES AND COMPLEX BIOLOGICS R&D TO AID GROWTH 156
10.8 MASS SPECTROMETRY 159
10.8.1 INVESTMENT IN ADVANCED INSTRUMENTATION AND DATA-DRIVEN WORKFLOWS TO DRIVE MARKET 159
10.9 OTHER TECHNOLOGIES 163
11 DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS 167
11.1 INTRODUCTION 168
11.2 TARGET IDENTIFICATION 168
11.2.1 INCREASING CLINICAL DATA VOLUME TO BOOST MARKET 168
11.3 TARGET VALIDATION 172
11.3.1 INCREASING TECHNOLOGICAL ADVANCEMENTS TO PROMOTE GROWTH 172
11.4 HIT-TO-LEAD IDENTIFICATION 175
11.4.1 GROWING ADOPTION OF MULTI-DISCIPLINARY APPROACHES TO DRIVE MARKET 175
11.5 LEAD OPTIMIZATION 179
11.5.1 INCREASING FOCUS ON REDUCING LATE-STAGE ATTRITION AND INCREASING PROBABILITY OF THERAPEUTIC SUCCESS TO FUEL MARKET 179
11.6 CANDIDATE VALIDATION 182
11.6.1 INCREASING COMPLEXITY OF THERAPEUTIC MODALITIES TO SUSTAIN GROWTH 182
12 DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA 186
12.1 INTRODUCTION 187
12.2 ONCOLOGY 187
12.2.1 SHIFT TOWARD PRECISION ONCOLOGY TO PROMOTE GROWTH 187

12.3 INFECTIOUS DISEASES 191
12.3.1 RISING ANTIMICROBIAL RESISTANCE AND AI-DRIVEN INNOVATIONS TO DRIVE MARKET 191
12.4 CARDIOVASCULAR DISEASES 194
12.4.1 INCREASING PREVALENCE OF CARDIOVASCULAR RISK FACTORS TO BOOST MARKET 194
12.5 NEUROLOGICAL DISEASES 198
12.5.1 INTEGRATION OF ADVANCED MODELS AND STRATEGIC INVESTMENTS TO FUEL MARKET 198
12.6 ENDOCRINE & METABOLIC DISORDERS 201
12.6.1 RISING PREVALENCE OF TYPE 2 DIABETES, OBESITY, AND ASSOCIATED METABOLIC SYNDROMES TO DRIVE MARKET 201
12.7 AUTOIMMUNE DISORDERS 205
12.7.1 WIDESPREAD ADOPTION OF BIOLOGICS AND SMALL MOLECULES TO PROPEL MARKET 205
12.8 OTHER THERAPEUTIC AREAS 208
13 DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER 212
13.1 INTRODUCTION 213
13.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 213
13.2.1 TECHNOLOGY INTEGRATION AND STRATEGIC PARTNERSHIPS TO CONTRBUTE TO GROWTH 213
13.3 ACADEMIC & RESEARCH INSTITUTES 217
13.3.1 RISING PUBLIC AND PRIVATE RESEARCH FUNDING AND STRONGER ACADEMIC–INDUSTRY COLLABORATION FRAMEWORKS TO AUGMENT GROWTH 217
13.4 CONTRACT RESEARCH ORGANIZATIONS (CROS) 220
13.4.1 INCREASING R&D OUTSOURCING TO EXPEDITE GROWTH 220
14 DRUG DISCOVERY TECHNOLOGIES MARKET, BY REGION 224
14.1 INTRODUCTION 225
14.2 NORTH AMERICA 225
14.2.1 US 230
14.2.1.1 Expanding network of cross-border partnerships and investments to expedite growth 230
14.2.2 CANADA 233
14.2.2.1 Increasing adoption of AI and open-science models to accelerate growth 233
14.3 EUROPE 237
14.3.1 GERMANY 241
14.3.1.1 Strong network of publicly funded research institutes, contract research organizations, and pharmaceutical developers to boost market 241
14.3.2 UK 244
14.3.2.1 Increasing focus on next-generation computational platforms to promote growth 244
14.3.3 FRANCE 248
14.3.3.1 Robust innovation ecosystem and AI-enabled research to propel market 248
14.3.4 ITALY 251
14.3.4.1 Rising research funding to contribute to growth 251
14.3.5 SPAIN 255
14.3.5.1 Well-established network of research centers and universities to boost market 255
14.3.6 REST OF EUROPE 258
14.4 ASIA PACIFIC 262
14.4.1 CHINA 266
14.4.1.1 Global partnerships to propel market 266
14.4.2 JAPAN 270
14.4.2.1 Rising integration of AI and international partnerships to favor growth 270
14.4.3 INDIA 273
14.4.3.1 Domestic infrastructure enhancements and government initiatives to support growth 273
14.4.4 AUSTRALIA 277
14.4.4.1 Rising adoption of artificial intelligence and advanced computational tools to foster growth 277
14.4.5 SOUTH KOREA 280
14.4.5.1 Favorable public policies to support growth 280
14.4.6 REST OF ASIA PACIFIC 284
14.5 LATIN AMERICA 287
14.5.1 BRAZIL 291
14.5.1.1 Public-private collaborations to bolster growth 291
14.5.2 MEXICO 295
14.5.2.1 Rising demand for AI-powered research to support growth 295
14.5.3 REST OF LATIN AMERICA 298
14.6 MIDDLE EAST 302
14.6.1 GCC COUNTRIES 305
14.6.1.1 Saudi Arabia 309
14.6.1.1.1 Increasing focus on regulatory reform, research funding, and international partnerships to boost market 309
14.6.1.2 UAE 312
14.6.1.2.1 Strong government vision and cross-sector partnerships to aid growth 312
14.6.1.3 Rest of GCC countries 316
14.6.2 REST OF MIDDLE EAST 319
14.7 AFRICA 323
14.7.1 STRATEGIC PARTNERSHIPS AND CAPACITY BUILDING INITIATIVES TO PROPEL MARKET 323

15 COMPETITIVE LANDSCAPE 327
15.1 OVERVIEW 327
15.2 KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN 327
15.3 REVENUE ANALYSIS 329
15.4 MARKET SHARE ANALYSIS 329
15.5 BRAND/PRODUCT COMPARISON 332
15.5.1 THERMO FISHER SCIENTIFIC INC. 333
15.5.2 MERCK KGAA 333
15.5.3 AGILENT TECHNOLOGIES, INC. 333
15.5.4 REVVITY 333
15.5.5 ILLUMINA, INC. 333
15.6 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 333
15.6.1 STARS 334
15.6.2 EMERGING LEADERS 334
15.6.3 PERVASIVE PLAYERS 334
15.6.4 PARTICIPANTS 334
15.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 336
15.6.5.1 Company footprint 336
15.6.5.2 Region footprint 337
15.6.5.3 Product footprint 338
15.6.5.4 Technology footprint 339
15.6.5.5 Process footprint 340
15.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 341
15.7.1 PROGRESSIVE COMPANIES 341
15.7.2 RESPONSIVE COMPANIES 341
15.7.3 DYNAMIC COMPANIES 341
15.7.4 STARTING BLOCKS 341
15.7.5 COMPETITIVE BENCHMARKING 343
15.7.5.1 Detailed list of key startups/SMEs 343
15.7.5.2 Competitive benchmarking of key startups/SMEs 344
15.8 COMPANY VALUATION AND FINANCIAL METRICS 345
15.9 COMPETITIVE SCENARIO 346
15.9.1 PRODUCT LAUNCHES 346
15.9.2 DEALS 347
15.9.3 EXPANSIONS 348
15.9.4 OTHER DEVELOPMENTS 348
16 COMPANY PROFILES 349
16.1 KEY PLAYERS 349
16.1.1 THERMO FISHER SCIENTIFIC INC. 349
16.1.1.1 Business overview 349
16.1.1.2 Products offered 350
16.1.1.3 Recent developments 353
16.1.1.3.1 Product launches 353
16.1.1.3.2 Deals 354
16.1.1.3.3 Expansions 354
16.1.1.4 MnM view 354
16.1.1.4.1 Key strengths/Right to win 354
16.1.1.4.2 Strategic choices 355
16.1.1.4.3 Weaknesses/Competitive threats 355
16.1.2 MERCK KGAA 356
16.1.2.1 Business overview 356
16.1.2.2 Products offered 357
16.1.2.3 Recent developments 358
16.1.2.3.1 Deals 358
16.1.2.3.2 Expansions 359
16.1.2.4 MnM view 359
16.1.2.4.1 Key strengths/Right to win 359
16.1.2.4.2 Strategic choices 359
16.1.2.4.3 Weaknesses/Competitive threats 359
16.1.3 AGILENT TECHNOLOGIES, INC. 360
16.1.3.1 Business overview 360
16.1.3.2 Products offered 361
16.1.3.3 Recent developments 363
16.1.3.3.1 Product launches 363
16.1.3.3.2 Expansions 364
16.1.3.4 MnM view 364
16.1.3.4.1 Key strengths/Right to win 364
16.1.3.4.2 Strategic choices 364
16.1.3.4.3 Weaknesses/Competitive threats 364
16.1.4 REVVITY 365
16.1.4.1 Business overview 365
16.1.4.2 Products offered 366
16.1.4.3 Recent developments 368
16.1.4.3.1 Product launches 368
16.1.4.3.2 Deals 368
16.1.4.3.3 Expansions 368
16.1.4.4 MnM view 369
16.1.4.4.1 Key strengths/Right to win 369
16.1.4.4.2 Strategic choices 369
16.1.4.4.3 Weaknesses/Competitive threats 369

16.1.5 ILLUMINA, INC. 370
16.1.5.1 Business overview 370
16.1.5.2 Products offered 371
16.1.5.3 Recent developments 372
16.1.5.3.1 Product launches 372
16.1.5.3.2 Deals 373
16.1.5.3.3 Expansions 373
16.1.5.3.4 Other developments 374
16.1.5.4 MnM view 374
16.1.5.4.1 Key strengths/Right to win 374
16.1.5.4.2 Strategic choices 374
16.1.5.4.3 Weaknesses/Competitive threats 374
16.1.6 DANAHER CORPORATION 375
16.1.6.1 Business overview 375
16.1.6.2 Products offered 376
16.1.6.3 Recent developments 380
16.1.6.3.1 Product launches 380
16.1.6.3.2 Deals 380
16.1.6.3.3 Expansions 381
16.1.6.4 MnM view 381
16.1.6.4.1 Key strengths/Right to win 381
16.1.6.4.2 Strategic choices 381
16.1.6.4.3 Weaknesses/Competitive threats 381
16.1.7 F. HOFFMANN-LA ROCHE LTD 382
16.1.7.1 Business overview 382
16.1.7.2 Products offered 383
16.1.7.3 Recent developments 385
16.1.7.3.1 Product launches 385
16.1.7.3.2 Deals 385
16.1.7.3.3 Other developments 385
16.1.8 BRUKER 386
16.1.8.1 Business overview 386
16.1.8.2 Products offered 387
16.1.8.3 Recent developments 388
16.1.8.3.1 Product launches 388
16.1.8.3.2 Deals 389
16.1.8.3.3 Expansions 389
16.1.9 QIAGEN 390
16.1.9.1 Business overview 390
16.1.9.2 Products offered 391
16.1.9.3 Recent developments 392
16.1.9.3.1 Product launches 392
16.1.9.3.2 Deals 393
16.1.9.3.3 Expansions 393
16.1.10 BIO-RAD LABORATORIES, INC. 394
16.1.10.1 Business overview 394
16.1.10.2 Products offered 395
16.1.10.3 Recent developments 397
16.1.10.3.1 Product launches 397
16.1.10.3.2 Deals 397
16.1.11 TECAN TRADING AG 398
16.1.11.1 Business overview 398
16.1.11.2 Products offered 400
16.1.12 TAKARA BIO INC. 401
16.1.12.1 Business overview 401
16.1.12.2 Products offered 402
16.1.12.3 Recent developments 403
16.1.12.3.1 Product launches 403
16.1.13 CORNING INCORPORATED 404
16.1.13.1 Business overview 404
16.1.13.2 Products offered 406
16.1.14 HAMILTON COMPANY 407
16.1.14.1 Business overview 407
16.1.14.2 Products offered 407
16.1.14.3 Recent developments 408
16.1.14.3.1 Product launches 408
16.1.14.3.2 Deals 408
16.1.15 PACBIO 409
16.1.15.1 Business overview 409
16.1.15.2 Products offered 410
16.1.15.3 Recent developments 412
16.1.15.3.1 Product launches 412
16.1.15.3.2 Expansions 412
16.1.16 OXFORD NANOPORE TECHNOLOGIES PLC 413
16.1.16.1 Business overview 413
16.1.16.2 Products offered 415
16.1.16.3 Recent developments 416
16.1.16.3.1 Product launches 416
16.1.16.3.2 Deals 416
16.1.17 PROMEGA CORPORATION 417
16.1.17.1 Business overview 417
16.1.17.2 Products offered 418

16.1.18 WATERS CORPORATION 419
16.1.18.1 Business overview 419
16.1.18.2 Products offered 421
16.1.18.3 Recent developments 422
16.1.18.3.1 Product launches 422
16.1.18.3.2 Deals 422
16.1.19 SARTORIUS AG 423
16.1.19.1 Business overview 423
16.1.19.2 Products offered 425
16.1.19.3 Recent developments 426
16.1.19.3.1 Deals 426
16.1.20 BD 427
16.1.20.1 Business overview 427
16.1.20.2 Products offered 428
16.1.20.3 Recent developments 429
16.1.20.3.1 Product launches 429
16.1.20.3.2 Deals 430
16.1.21 EPPENDORF SE 431
16.1.21.1 Business overview 431
16.1.21.2 Products offered 433
16.1.21.3 Recent developments 434
16.1.21.3.1 Deals 434
16.1.22 SHIMADZU CORPORATION 435
16.1.22.1 Business overview 435
16.1.22.2 Business overview 435
16.1.22.3 Products offered 436
16.1.23 AURORA BIOMED INC. 438
16.1.23.1 Business overview 438
16.1.23.2 Products offered 438
16.1.24 STANDARD BIOTOOLS 439
16.1.24.1 Business overview 439
16.1.24.2 Products offered 440
16.1.25 JEOL LTD. 441
16.1.25.1 Business overview 441
16.1.25.2 Products offered 443
16.1.26 GILSON INCORPORATED 444
16.1.26.1 Business overview 444
16.1.26.2 Products offered 444
16.1.27 BIOMÉRIEUX 445
16.1.27.1 Business overview 445
16.1.27.2 Products offered 446

16.1.28 GREINER AG 447
16.1.28.1 Business overview 447
16.1.28.2 Products offered 448
16.1.29 BGI GROUP 449
16.1.29.1 Business overview 449
16.1.29.2 Products offered 449
16.1.30 PORVAIR 451
16.1.30.1 Business overview 451
16.1.30.2 Products offered 452
16.2 OTHER PLAYERS 453
16.2.1 POLARIS GENOMICS 453
16.2.2 BICO 454
16.2.3 CREATIVE BIOARRAY 455
16.2.4 SPHERE BIO 455
16.2.5 GENSCRIPT 456
16.2.6 SCHRÖDINGER, INC. 457
16.2.7 LECO CORPORATION 458
16.2.8 TRANSGEN BIOTECH CO., LTD 459
16.2.9 BMG LABTECH 460
16.2.10 NANOTEMPER TECHNOLOGIES 461
16.2.11 MGI TECH CO., LTD. 462
16.2.12 ARACELI BIOSCIENCES 463
16.2.13 ANALYTIK JENA GMBH+CO. KG 464
16.2.14 BIOSOLVEIT GMBH 465
16.2.15 EVOSEP 466
17 RESEARCH METHODOLOGY 467
17.1 RESEARCH DATA 467
17.1.1 SECONDARY DATA 468
17.1.1.1 Key data from secondary sources 468
17.1.2 PRIMARY DATA 469
17.1.2.1 Key data from primary sources 469
17.1.2.2 Key primary participants 469
17.1.2.3 Breakdown of primary interviews 470
17.1.2.4 Key industry insights 471
17.2 MARKET SIZE ESTIMATION 472
17.2.1 BOTTOM-UP APPROACH 472
17.2.2 TOP-DOWN APPROACH 474
17.2.3 BASE NUMBER CALCULATION 475
17.3 GROWTH FORECAST MODEL 476
17.4 DATA TRIANGULATION 477
17.5 FACTOR ANALYSIS 478
17.6 RESEARCH ASSUMPTIONS 478
17.7 RESEARCH LIMITATIONS AND RISK ASSESSMENT 479
18 APPENDIX 481
18.1 DISCUSSION GUIDE 481
18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 485
18.3 CUSTOMIZATION OPTIONS 487
18.4 RELATED REPORTS 487
18.5 AUTHOR DETAILS 488

LIST OF TABLES

TABLE 1 DRUG DISCOVERY TECHNOLOGIES MARKET: INCLUSIONS AND EXCLUSIONS 44
TABLE 2 DRUG DISCOVERY TECHNOLOGIES MARKET: IMPACT ANALYSIS
OF MARKET DYNAMICS 57
TABLE 3 DRUG DISCOVERY TECHNOLOGIES MARKET: PORTER’S FIVE FORCES 64
TABLE 4 DRUG DISCOVERY TECHNOLOGIES MARKET: ROLE OF COMPANIES IN ECOSYSTEM 70
TABLE 5 AVERAGE SELLING PRICE OF END USERS, BY KEY PLAYERS, 2024 71
TABLE 6 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER,
2022–2024 (USD MILLION) 71
TABLE 7 AVERAGE SELLING PRICE TREND, BY TECHNOLOGY, 2022−2024 73
TABLE 8 AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY REGION,
2022–2024 (USD MILLION) 74
TABLE 9 AVERAGE SELLING PRICE TREND OF CONSUMABLES, BY REGION,
2022–2024 (USD MILLION) 74
TABLE 10 IMPORT DATA FOR HS CODE 3822.00, BY COUNTRY,
2020–2024 (USD THOUSAND) 76
TABLE 11 EXPORT DATA FOR HS CODE 3822.00, BY COUNTRY,
2020–2024 (USD THOUSAND) 76
TABLE 12 IMPORT DATA FOR HS CODE 9027.00, BY COUNTRY,
2020–2024 (USD THOUSAND) 77
TABLE 13 EXPORT DATA FOR HS CODE 9027.00, BY COUNTRY,
2020–2024 (USD THOUSAND) 78
TABLE 14 DRUG DISCOVERY TECHNOLOGIES MARKET: KEY CONFERENCES AND
EVENTS, 2025–2026 79
TABLE 15 US ADJUSTED RECIPROCAL TARIFF RATES 82
TABLE 16 KEY PRODUCT-RELATED TARIFF: HS CODES FOR PRODUCTS RELEVANT TO DRUG DISCOVERY TECHNOLOGIES 85
TABLE 17 CRITICAL COMPONENTS LIKELY EXPOSED TO TARIFF CHANGES 86
TABLE 18 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2014–2024 91
TABLE 19 LIST OF KEY PATENTS IN DRUG DISCOVERY TECHNOLOGIES MARKET, 2023–2025 93
TABLE 20 CASE STUDIES OF AI IMPLEMENTATION IN DRUG DISCOVERY
TECHNOLOGIES MARKET 96
TABLE 21 CLIENT’S READINESS TO ADOPT GENERATIVE MOLECULAR DESIGN IN DRUG DISCOVERY TECHNOLOGIES MARKET 97
TABLE 22 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 98
TABLE 23 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND
OTHER ORGANIZATIONS 98
TABLE 24 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 99
TABLE 25 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT
AGENCIES, AND OTHER ORGANIZATIONS 100
TABLE 26 DRUG DISCOVERY TECHNOLOGIES MARKET: VENDOR CERTIFICATIONS 106
TABLE 27 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT 108
TABLE 28 KEY BUYING CRITERIA, BY END USER 108
TABLE 29 DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 112
TABLE 30 DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES,
BY REGION, 2023–2030 (USD MILLION) 113
TABLE 31 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION) 113
TABLE 32 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION) 114
TABLE 33 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION) 114
TABLE 34 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION) 115
TABLE 35 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES, BY REGION, 2023–2030 (USD MILLION) 115
TABLE 36 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2023–2030 (USD MILLION) 115
TABLE 37 DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS, BY REGION, 2023–2030 (USD MILLION) 116
TABLE 38 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION) 117
TABLE 39 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS,
BY COUNTRY, 2023–2030 (USD MILLION) 117
TABLE 40 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS,
BY COUNTRY, 2023–2030 (USD MILLION) 118
TABLE 41 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION) 118
TABLE 42 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS,
BY REGION, 2023–2030 (USD MILLION) 119
TABLE 43 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INSTRUMENTS, BY COUNTRY, 2023–2030 (USD MILLION) 119
TABLE 44 DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY REGION, 2023–2030 (USD MILLION) 120
TABLE 45 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION) 120
TABLE 46 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION) 121
TABLE 47 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION) 121
TABLE 48 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION) 122
TABLE 49 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY REGION, 2023–2030 (USD MILLION) 122
TABLE 50 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR BIOINFORMATICS TOOLS & SOFTWARE, BY COUNTRY, 2023–2030 (USD MILLION) 122
TABLE 51 DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 124
TABLE 52 DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 125
TABLE 53 DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION) 125
TABLE 54 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY COUNTRY,
2023–2030 (USD MILLION) 126
TABLE 55 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 126
TABLE 56 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 127
TABLE 57 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY COUNTRY,
2023–2030 (USD MILLION) 127
TABLE 58 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY REGION,
2023–2030 (USD MILLION) 128
TABLE 59 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING (HTS) TECHNOLOGIES, BY COUNTRY,
2023–2030 (USD MILLION) 128
TABLE 60 DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY REGION, 2023–2030 (USD MILLION) 129
TABLE 61 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY COUNTRY, 2023–2030 (USD MILLION) 129
TABLE 62 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY COUNTRY, 2023–2030 (USD MILLION) 130
TABLE 63 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY COUNTRY, 2023–2030 (USD MILLION) 130
TABLE 64 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY COUNTRY, 2023–2030 (USD MILLION) 131
TABLE 65 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY REGION, 2023–2030 (USD MILLION) 131
TABLE 66 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOMATED LIQUID HANDLING, BY COUNTRY, 2023–2030 (USD MILLION) 131
TABLE 67 DRUG DISCOVERY TECHNOLOGIES MARKET FOR MICROPLATE-BASED HTS,
BY REGION, 2023–2030 (USD MILLION) 132
TABLE 68 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MICROPLATE-BASED HTS, BY COUNTRY, 2023–2030 (USD MILLION) 133
TABLE 69 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MICROPLATE-BASED HTS, BY COUNTRY, 2023–2030 (USD MILLION) 133
TABLE 70 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
MICROPLATE- BASED HTS, BY COUNTRY, 2023–2030 (USD MILLION) 134
TABLE 71 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
MICROPLATE-BASED HTS, BY COUNTRY, 2023–2030 (USD MILLION) 134
TABLE 72 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
MICROPLATE-BASED HTS, BY REGION, 2023–2030 (USD MILLION) 135
TABLE 73 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
MICROPLATE-BASED HTS, BY COUNTRY, 2023–2030 (USD MILLION) 135
TABLE 74 DRUG DISCOVERY TECHNOLOGIES MARKET FOR LAB-ON-A CHIP,
BY REGION, 2023–2030 (USD MILLION) 136
TABLE 75 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
LAB-ON-A CHIP, BY COUNTRY, 2023–2030 (USD MILLION) 136
TABLE 76 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LAB-ON-A CHIP,
BY COUNTRY, 2023–2030 (USD MILLION) 137
TABLE 77 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LAB-ON-A CHIP,
BY COUNTRY, 2023–2030 (USD MILLION) 137
TABLE 78 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LAB-ON-A CHIP, BY COUNTRY, 2023–2030 (USD MILLION) 138
TABLE 79 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LAB-ON-A CHIP,
BY REGION, 2023–2030 (USD MILLION) 138
TABLE 80 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
LAB-ON-A CHIP, BY COUNTRY, 2023–2030 (USD MILLION) 138
TABLE 81 DRUG DISCOVERY TECHNOLOGIES MARKET FOR LABEL-FREE TECHNOLOGY,
BY REGION, 2023–2030 (USD MILLION) 139
TABLE 82 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
LABEL-FREE TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 140
TABLE 83 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
LABEL-FREE TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 140
TABLE 84 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET
FOR LABEL-FREE TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 141
TABLE 85 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET
FOR LABEL-FREE TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 141
TABLE 86 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LABEL-FREE TECHNOLOGY, BY REGION, 2023–2030 (USD MILLION) 142
TABLE 87 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET
FOR LABEL-FREE TECHNOLOGY, BY COUNTRY, 2023–2030 (USD MILLION) 142
TABLE 88 DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2023–2030 (USD MILLION) 143
TABLE 89 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION) 143
TABLE 90 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION) 144
TABLE 91 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION) 144
TABLE 92 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION) 145
TABLE 93 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2023–2030 (USD MILLION) 145
TABLE 94 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023–2030 (USD MILLION) 145
TABLE 95 DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2023–2030 (USD MILLION) 146
TABLE 96 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION) 147
TABLE 97 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION) 147
TABLE 98 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION) 148
TABLE 99 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION) 148
TABLE 100 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2023–2030 (USD MILLION) 149
TABLE 101 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION) 149
TABLE 102 DRUG DISCOVERY TECHNOLOGIES MARKET FOR IN-SILICO/ AI-BASED DRUG DISCOVERY TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION) 150
TABLE 103 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR IN-SILICO/
AI-BASED DRUG DISCOVERY TECHNOLOGIES, BY COUNTRY,
2023–2030 (USD MILLION) 150
TABLE 104 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR IN-SILICO/ AI-BASED DRUG DISCOVERY TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 151
TABLE 105 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR IN-SILICO/
AI-BASED DRUG DISCOVERY TECHNOLOGIES, BY COUNTRY,
2023–2030 (USD MILLION) 151
TABLE 106 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR IN-SILICO/
AI-BASED DRUG DISCOVERY TECHNOLOGIES, BY COUNTRY,
2023–2030 (USD MILLION) 152
TABLE 107 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR IN-SILICO/
AI-BASED DRUG DISCOVERY TECHNOLOGIES, BY COUNTRY,
2023–2030 (USD MILLION) 152
TABLE 108 DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY CRYSTALLOGRAPHY,
BY REGION, 2023–2030 (USD MILLION) 153
TABLE 109 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY CRYSTALLOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION) 153
TABLE 110 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY CRYSTALLOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION) 154
TABLE 111 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY CRYSTALLOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION) 154
TABLE 112 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY CRYSTALLOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION) 155
TABLE 113 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY CRYSTALLOGRAPHY, BY REGION, 2023–2030 (USD MILLION) 155
TABLE 114 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR X-RAY CRYSTALLOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION) 155
TABLE 115 DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY,
BY REGION, 2023–2030 (USD MILLION) 156
TABLE 116 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION) 157
TABLE 117 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY,
BY COUNTRY, 2023–2030 (USD MILLION) 157
TABLE 118 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION) 158
TABLE 119 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION) 158
TABLE 120 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY, BY REGION, 2023–2030 (USD MILLION) 159
TABLE 121 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CHROMATOGRAPHY, BY COUNTRY, 2023–2030 (USD MILLION) 159
TABLE 122 DRUG DISCOVERY TECHNOLOGIES MARKET FOR MASS SPECTROMETRY,
BY REGION, 2023–2030 (USD MILLION) 160
TABLE 123 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023–2030 (USD MILLION) 160
TABLE 124 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
MASS SPECTROMETRY, BY COUNTRY, 2023–2030 (USD MILLION) 161
TABLE 125 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023–2030 (USD MILLION) 161
TABLE 126 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023–2030 (USD MILLION) 162
TABLE 127 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MASS SPECTROMETRY, BY REGION, 2023–2030 (USD MILLION) 162
TABLE 128 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR MASS SPECTROMETRY, BY COUNTRY, 2023–2030 (USD MILLION) 162
TABLE 129 DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER TECHNOLOGIES,
BY REGION, 2023–2030 (USD MILLION) 163
TABLE 130 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 164
TABLE 131 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 164
TABLE 132 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 165
TABLE 133 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET
FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 165
TABLE 134 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET
FOR OTHER TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION) 166
TABLE 135 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET
FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 166
TABLE 136 DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 168
TABLE 137 DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION,
BY REGION, 2023–2030 (USD MILLION) 169
TABLE 138 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 169
TABLE 139 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 170
TABLE 140 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 170
TABLE 141 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 171
TABLE 142 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION, BY REGION, 2023–2030 (USD MILLION) 171
TABLE 143 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 171
TABLE 144 DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET VALIDATION,
BY REGION, 2023–2030 (USD MILLION) 172
TABLE 145 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION) 173
TABLE 146 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET VALIDATION,
BY COUNTRY, 2023–2030 (USD MILLION) 173
TABLE 147 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION) 174
TABLE 148 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION) 174
TABLE 149 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET VALIDATION, BY REGION, 2023–2030 (USD MILLION) 175
TABLE 150 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR TARGET VALIDATION,BY COUNTRY, 2023–2030 (USD MILLION) 175
TABLE 151 DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIT-TO-LEAD IDENTIFICATION,
BY REGION, 2023–2030 (USD MILLION) 176
TABLE 152 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 176
TABLE 153 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 177
TABLE 154 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 177
TABLE 155 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 178
TABLE 156 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
HIT-TO-LEAD IDENTIFICATION, BY REGION, 2023–2030 (USD MILLION) 178
TABLE 157 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
HIT-TO-LEAD IDENTIFICATION, BY COUNTRY, 2023–2030 (USD MILLION) 178
TABLE 158 DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION,
BY REGION, 2023–2030 (USD MILLION) 179
TABLE 159 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023–2030 (USD MILLION) 180
TABLE 160 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION,
BY COUNTRY, 2023–2030 (USD MILLION) 180
TABLE 161 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023–2030 (USD MILLION) 181
TABLE 162 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023–2030 (USD MILLION) 181
TABLE 163 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION, BY REGION, 2023–2030 (USD MILLION) 182
TABLE 164 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR LEAD OPTIMIZATION, BY COUNTRY, 2023–2030 (USD MILLION) 182
TABLE 165 DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION,
BY REGION, 2023–2030 (USD MILLION) 183
TABLE 166 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION) 183
TABLE 167 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION) 184
TABLE 168 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION) 184
TABLE 169 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION) 185
TABLE 170 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION, BY REGION, 2023–2030 (USD MILLION) 185
TABLE 171 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CANDIDATE VALIDATION, BY COUNTRY, 2023–2030 (USD MILLION) 185
TABLE 172 DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA,
2023–2030 (USD MILLION) 187
TABLE 173 DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY, BY REGION,
2023–2030 (USD MILLION) 188
TABLE 174 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY,
BY COUNTRY, 2023–2030 (USD MILLION) 188
TABLE 175 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY,
BY COUNTRY, 2023–2030 (USD MILLION) 189
TABLE 176 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY,
BY COUNTRY, 2023–2030 (USD MILLION) 189
TABLE 177 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY,
BY COUNTRY, 2023–2030 (USD MILLION) 190
TABLE 178 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY,
BY REGION, 2023–2030 (USD MILLION) 190
TABLE 179 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ONCOLOGY,
BY COUNTRY, 2023–2030 (USD MILLION) 190
TABLE 180 DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES,
BY REGION, 2023–2030 (USD MILLION) 191
TABLE 181 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 192
TABLE 182 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 192
TABLE 183 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 193
TABLE 184 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 193
TABLE 185 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION) 194
TABLE 186 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 194
TABLE 187 DRUG DISCOVERY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES,
BY REGION, 2023–2030 (USD MILLION) 195
TABLE 188 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 195
TABLE 189 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 196
TABLE 190 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 196
TABLE 191 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 197
TABLE 192 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023–2030 (USD MILLION) 197
TABLE 193 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 197
TABLE 194 DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEUROLOGICAL DISEASES,
BY REGION, 2023–2030 (USD MILLION) 198
TABLE 195 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 199
TABLE 196 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 199
TABLE 197 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 200
TABLE 198 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 200
TABLE 199 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2023–2030 (USD MILLION) 201
TABLE 200 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION) 201
TABLE 201 DRUG DISCOVERY TECHNOLOGIES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023–2030 (USD MILLION) 202
TABLE 202 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 202
TABLE 203 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 203
TABLE 204 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 203
TABLE 205 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 204
TABLE 206 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023–2030 (USD MILLION) 204
TABLE 207 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 204
TABLE 208 DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS,
BY REGION, 2023–2030 (USD MILLION) 205
TABLE 209 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 206
TABLE 210 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 206
TABLE 211 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 207
TABLE 212 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 207
TABLE 213 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS, BY REGION, 2023–2030 (USD MILLION) 208
TABLE 214 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISORDERS, BY COUNTRY, 2023–2030 (USD MILLION) 208
TABLE 215 DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC AREAS,
BY REGION, 2023–2030 (USD MILLION) 209
TABLE 216 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 209
TABLE 217 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 210
TABLE 218 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 210
TABLE 219 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 211
TABLE 220 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION) 211
TABLE 221 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR
OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2030 (USD MILLION) 211
TABLE 222 DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 213
TABLE 223 DRUG DISCOVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 214
TABLE 224 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2023–2030 (USD MILLION) 214
TABLE 225 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 215
TABLE 226 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 215
TABLE 227 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2023–2030 (USD MILLION) 216
TABLE 228 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 216
TABLE 229 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2023–2030 (USD MILLION) 216
TABLE 230 DRUG DISCOVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 217
TABLE 231 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 218
TABLE 232 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 218
TABLE 233 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 219
TABLE 234 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 219
TABLE 235 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 220
TABLE 236 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 220
TABLE 237 DRUG DISCOVERY TECHNOLOGIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2023–2030 (USD MILLION) 221
TABLE 238 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2023–2030 (USD MILLION) 221
TABLE 239 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2023–2030 (USD MILLION) 222
TABLE 240 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2023–2030 (USD MILLION) 222
TABLE 241 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2023–2030 (USD MILLION) 223
TABLE 242 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2023–2030 (USD MILLION) 223
TABLE 243 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2023–2030 (USD MILLION) 223
TABLE 244 DRUG DISCOVERY TECHNOLOGIES MARKET, BY REGION,
2023–2030 (USD MILLION) 225
TABLE 245 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 226
TABLE 246 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET,
BY PRODUCT, 2023–2030 (USD MILLION) 227
TABLE 247 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 227
TABLE 248 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 228
TABLE 249 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET,
BY PROCESS, 2023–2030 (USD MILLION) 228
TABLE 250 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 229
TABLE 251 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET,
BY END USER, 2023–2030 (USD MILLION) 229
TABLE 252 US: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 230
TABLE 253 US: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 231
TABLE 254 US: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 231
TABLE 255 US: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 232
TABLE 256 US: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA,
2023–2030 (USD MILLION) 232
TABLE 257 US: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 233
TABLE 258 CANADA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 234
TABLE 259 CANADA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 234
TABLE 260 CANADA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 235
TABLE 261 CANADA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 235
TABLE 262 CANADA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 236
TABLE 263 CANADA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 236
TABLE 264 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 237
TABLE 265 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 238
TABLE 266 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 238
TABLE 267 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 239
TABLE 268 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 239
TABLE 269 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 240
TABLE 270 EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 240
TABLE 271 GERMANY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 241
TABLE 272 GERMANY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 242
TABLE 273 GERMANY: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 242
TABLE 274 GERMANY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 243
TABLE 275 GERMANY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 243
TABLE 276 GERMANY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 244
TABLE 277 UK: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 245
TABLE 278 UK: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 245
TABLE 279 UK: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 246
TABLE 280 UK: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 246
TABLE 281 UK: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA,
2023–2030 (USD MILLION) 247
TABLE 282 UK: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 247
TABLE 283 FRANCE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 248
TABLE 284 FRANCE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 249
TABLE 285 FRANCE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 249
TABLE 286 FRANCE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 250
TABLE 287 FRANCE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 250
TABLE 288 FRANCE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 251
TABLE 289 ITALY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 252
TABLE 290 ITALY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 252
TABLE 291 ITALY: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 253
TABLE 292 ITALY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 253
TABLE 293 ITALY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA,
2023–2030 (USD MILLION) 254
TABLE 294 ITALY: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 254
TABLE 295 SPAIN: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 255
TABLE 296 SPAIN: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 256
TABLE 297 SPAIN: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 256
TABLE 298 SPAIN: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 257
TABLE 299 SPAIN: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 257
TABLE 300 SPAIN: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 258
TABLE 301 REST OF EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 259
TABLE 302 REST OF EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 259
TABLE 303 REST OF EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 260
TABLE 304 REST OF EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 260
TABLE 305 REST OF EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 261
TABLE 306 REST OF EUROPE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 261
TABLE 307 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 263
TABLE 308 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 263
TABLE 309 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 264
TABLE 310 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 264
TABLE 311 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 265
TABLE 312 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 265
TABLE 313 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 266
TABLE 314 CHINA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 267
TABLE 315 CHINA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 267
TABLE 316 CHINA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 268
TABLE 317 CHINA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 268
TABLE 318 CHINA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 269
TABLE 319 CHINA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 269
TABLE 320 JAPAN: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 270
TABLE 321 JAPAN: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 271
TABLE 322 JAPAN: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 271
TABLE 323 JAPAN: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 272
TABLE 324 JAPAN: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 272
TABLE 325 JAPAN: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 273
TABLE 326 INDIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 274
TABLE 327 INDIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 274
TABLE 328 INDIA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 275
TABLE 329 INDIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 275
TABLE 330 INDIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA,
2023–2030 (USD MILLION) 276
TABLE 331 INDIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 276
TABLE 332 AUSTRALIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 277
TABLE 333 AUSTRALIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 278
TABLE 334 AUSTRALIA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 278
TABLE 335 AUSTRALIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 279
TABLE 336 AUSTRALIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 279
TABLE 337 AUSTRALIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 280
TABLE 338 SOUTH KOREA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 281
TABLE 339 SOUTH KOREA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 281
TABLE 340 SOUTH KOREA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 282
TABLE 341 SOUTH KOREA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 282
TABLE 342 SOUTH KOREA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 283
TABLE 343 SOUTH KOREA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 283
TABLE 344 REST OF ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET,
BY PRODUCT, 2023–2030 (USD MILLION) 284
TABLE 345 REST OF ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 285
TABLE 346 REST OF ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 285
TABLE 347 REST OF ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET,
BY PROCESS, 2023–2030 (USD MILLION) 286
TABLE 348 REST OF ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 286
TABLE 349 REST OF ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET,
BY END USER, 2023–2030 (USD MILLION) 287
TABLE 350 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 288
TABLE 351 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 288
TABLE 352 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 289
TABLE 353 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 289
TABLE 354 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 290
TABLE 355 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 290
TABLE 356 LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET,
BY END USER, 2023–2030 (USD MILLION) 291
TABLE 357 BRAZIL: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 292
TABLE 358 BRAZIL: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 292
TABLE 359 BRAZIL: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 293
TABLE 360 BRAZIL: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 293
TABLE 361 BRAZIL: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 294
TABLE 362 BRAZIL: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 294
TABLE 363 MEXICO: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 295
TABLE 364 MEXICO: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 296
TABLE 365 MEXICO: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 296
TABLE 366 MEXICO: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 297
TABLE 367 MEXICO: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 297
TABLE 368 MEXICO: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 298
TABLE 369 REST OF LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET,
BY PRODUCT, 2023–2030 (USD MILLION) 299
TABLE 370 REST OF LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 299
TABLE 371 REST OF LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 300
TABLE 372 REST OF LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET,
BY PROCESS, 2023–2030 (USD MILLION) 300
TABLE 373 REST OF LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 301
TABLE 374 REST OF LATIN AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET,
BY END USER, 2023–2030 (USD MILLION) 301
TABLE 375 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 302
TABLE 376 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 302
TABLE 377 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 303
TABLE 378 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 303
TABLE 379 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 304
TABLE 380 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 304
TABLE 381 MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 305
TABLE 382 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 305
TABLE 383 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 306
TABLE 384 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 306
TABLE 385 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 307
TABLE 386 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 307
TABLE 387 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 308
TABLE 388 GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER, 2023–2030 (USD MILLION) 308
TABLE 389 SAUDI ARABIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 309
TABLE 390 SAUDI ARABIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 310
TABLE 391 SAUDI ARABIA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 310
TABLE 392 SAUDI ARABIA: DRUG DISCOVERY TECHNOLOGIES MARKET,
BY PROCESS,
2023–2030 (USD MILLION) 311
TABLE 393 SAUDI ARABIA: DRUG DISCOVERY TECHNOLOGIES MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 311
TABLE 394 SAUDI ARABIA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 312
TABLE 395 UAE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 313
TABLE 396 UAE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 313
TABLE 397 UAE: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 314
TABLE 398 UAE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 314
TABLE 399 UAE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA,
2023–2030 (USD MILLION) 315
TABLE 400 UAE: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 315
TABLE 401 REST OF GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET,
BY PRODUCT, 2023–2030 (USD MILLION) 316
TABLE 402 REST OF GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 317
TABLE 403 REST OF GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 317
TABLE 404 REST OF GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET,
BY PROCESS, 2023–2030 (USD MILLION) 318
TABLE 405 REST OF GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 318
TABLE 406 REST OF GCC COUNTRIES: DRUG DISCOVERY TECHNOLOGIES MARKET,
BY END USER, 2023–2030 (USD MILLION) 319
TABLE 407 REST OF MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET,
BY PRODUCT, 2023–2030 (USD MILLION) 320
TABLE 408 REST OF MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 320
TABLE 409 REST OF MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 321
TABLE 410 REST OF MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS, 2023–2030 (USD MILLION) 321
TABLE 411 REST OF MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET,
BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 322
TABLE 412 REST OF MIDDLE EAST: DRUG DISCOVERY TECHNOLOGIES MARKET,
BY END USER, 2023–2030 (USD MILLION) 322
TABLE 413 AFRICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PRODUCT,
2023–2030 (USD MILLION) 323
TABLE 414 AFRICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 324
TABLE 415 AFRICA: DRUG DISCOVERY TECHNOLOGIES MARKET FOR HIGH-THROUGHPUT SCREENING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION) 324
TABLE 416 AFRICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY PROCESS,
2023–2030 (USD MILLION) 325
TABLE 417 AFRICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION) 325
TABLE 418 AFRICA: DRUG DISCOVERY TECHNOLOGIES MARKET, BY END USER,
2023–2030 (USD MILLION) 326
TABLE 419 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DRUG DISCOVERY TECHNOLOGIES MARKET, JANUARY 2022–NOVEMBER 2025 327
TABLE 420 DRUG DISCOVERY TECHNOLOGIES MARKET: DEGREE OF COMPETITION 330
TABLE 421 DRUG DISCOVERY TECHNOLOGIES MARKET: REGION FOOTPRINT 337
TABLE 422 DRUG DISCOVERY TECHNOLOGIES MARKET: PRODUCT FOOTPRINT 338
TABLE 423 DRUG DISCOVERY TECHNOLOGIES MARKET: TECHNOLOGY FOOTPRINT 339
TABLE 424 DRUG DISCOVERY TECHNOLOGIES MARKET: PROCESS FOOTPRINT 340
TABLE 425 DRUG DISCOVERY TECHNOLOGIES MARKET: DETAILED LIST
OF KEY STARTUPS/SMES 343
TABLE 426 DRUG DISCOVERY TECHNOLOGIES MARKET: COMPETITIVE BENCHMARKING
OF KEY STARTUPS/SMES 344
TABLE 427 DRUG DISCOVERY TECHNOLOGIES MARKET: PRODUCT LAUNCHES,
JANUARY 2022–NOVEMBER 2025 346
TABLE 428 DRUG DISCOVERY TECHNOLOGIES MARKET: DEALS,
JANUARY 2022–NOVEMBER 2025 347
TABLE 429 DRUG DISCOVERY TECHNOLOGIES MARKET: EXPANSIONS,
JANUARY 2022–NOVEMBER 2025 348
TABLE 430 DRUG DISCOVERY TECHNOLOGIES MARKET: OTHER DEVELOPMENTS,
JANUARY 2022–NOVEMBER 2025 348
TABLE 431 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 349
TABLE 432 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 350
TABLE 433 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES, JANUARY 2022–NOVEMBER 2025 353
TABLE 434 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–NOVEMBER 2025 354
TABLE 435 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS,
JANUARY 2022–NOVEMBER 2025 354
TABLE 436 MERCK KGAA: COMPANY OVERVIEW 356
TABLE 437 MERCK KGAA: PRODUCTS OFFERED 357
TABLE 438 MERCK KGAA: DEALS, JANUARY 2022–NOVEMBER 2025 358
TABLE 439 MERCK KGAA: EXPANSIONS, JANUARY 2022–NOVEMBER 2025 359
TABLE 440 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 360
TABLE 441 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED 361
TABLE 442 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES,
JANUARY 2022–NOVEMBER 2025 363
TABLE 443 AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2022–NOVEMBER 2025 364
TABLE 444 REVVITY: COMPANY OVERVIEW 365
TABLE 445 REVVITY: PRODUCTS OFFERED 366
TABLE 446 REVVITY: PRODUCT LAUNCHES, JANUARY 2022–NOVEMBER 2025 368
TABLE 447 REVVITY: DEALS, JANUARY 2022–NOVEMBER 2025 368
TABLE 448 REVVITY: EXPANSIONS, JANUARY 2022–NOVEMBER 2025 368
TABLE 449 ILLUMINA, INC.: COMPANY OVERVIEW 370
TABLE 450 ILLUMINA, INC.: PRODUCTS OFFERED 371
TABLE 451 ILLUMINA, INC.: PRODUCT LAUNCHES, JANUARY 2022–NOVEMBER 2025 372
TABLE 452 ILLUMINA, INC.: DEALS, JANUARY 2022–NOVEMBER 2025 373
TABLE 453 ILLUMINA, INC.: EXPANSIONS, JANUARY 2022–NOVEMBER 2025 373
TABLE 454 ILLUMINA, INC.: OTHER DEVELOPMENTS, JANUARY 2022–NOVEMBER 2025 374
TABLE 455 DANAHER CORPORATION: COMPANY OVERVIEW 375
TABLE 456 DANAHER CORPORATION: PRODUCTS OFFERED 376
TABLE 457 DANAHER CORPORATION: PRODUCT LAUNCHES,
JANUARY 2022–NOVEMBER 2025 380
TABLE 458 DANAHER CORPORATION: DEALS, JANUARY 2022–NOVEMBER 2025 380
TABLE 459 DANAHER CORPORATION: EXPANSIONS, JANUARY 2022–NOVEMBER 2025 381
TABLE 460 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW 382
TABLE 461 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED 383
TABLE 462 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES,
JANUARY 2022–NOVEMBER 2025 385
TABLE 463 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2022–NOVEMBER 2025 385
TABLE 464 F. HOFFMANN-LA ROCHE LTD.: OTHER DEVELOPMENTS, JANUARY 2022–NOVEMBER 2025 385
TABLE 465 BRUKER: COMPANY OVERVIEW 386
TABLE 466 BRUKER: PRODUCTS OFFERED 387
TABLE 467 BRUKER: PRODUCT LAUNCHES, JANUARY 2022–NOVEMBER 2025 388
TABLE 468 BRUKER: DEALS, JANUARY 2022–NOVEMBER 2025 389
TABLE 469 BRUKER: EXPANSIONS, JANUARY 2022–NOVEMBER 2025 389
TABLE 470 QIAGEN: COMPANY OVERVIEW 390
TABLE 471 QIAGEN: PRODUCTS OFFERED 391
TABLE 472 QIAGEN: PRODUCT LAUNCHES, JANUARY 2022–NOVEMBER 2025 392
TABLE 473 QIAGEN: DEALS, JANUARY 2022–NOVEMBER 2025 393
TABLE 474 QIAGEN: EXPANSIONS, JANUARY 2022–NOVEMBER 2025 393
TABLE 475 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 394
TABLE 476 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED 395
TABLE 477 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES,
JANUARY 2022–NOVEMBER 2025 397
TABLE 478 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2022–NOVEMBER 2025 397
TABLE 479 TECAN TRADING AG: COMPANY OVERVIEW 398
TABLE 480 TECAN TRADING AG: PRODUCTS OFFERED 400
TABLE 481 TAKARA BIO INC.: COMPANY OVERVIEW 401
TABLE 482 TAKARA BIO INC.: PRODUCTS OFFERED 402
TABLE 483 TAKARA BIO INC.: PRODUCT LAUNCHES, JANUARY 2022–NOVEMBER 2025 403
TABLE 484 CORNING INCORPORATED: COMPANY OVERVIEW 404
TABLE 485 CORNING INCORPORATED: PRODUCTS OFFERED 406
TABLE 486 HAMILTON COMPANY: COMPANY OVERVIEW 407
TABLE 487 HAMILTON COMPANY: PRODUCTS OFFERED 407
TABLE 488 HAMILTON COMPANY: PRODUCT LAUNCHES 408
TABLE 489 HAMILTON COMPANY: DEALS 408
TABLE 490 PACBIO: COMPANY OVERVIEW 409
TABLE 491 PACBIO: PRODUCTS OFFERED 410
TABLE 492 PACBIO: PRODUCT LAUNCHES, JANUARY 2022–NOVEMBER 2025 412
TABLE 493 PACBIO: EXPANSIONS, JANUARY 2022–NOVEMBER 2025 412
TABLE 494 OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY OVERVIEW 413
TABLE 495 OXFORD NANOPORE TECHNOLOGIES PLC: PRODUCTS OFFERED 415
TABLE 496 OXFORD NANOPORE TECHNOLOGIES PLC.: PRODUCT LAUNCHES,
JANUARY 2022–NOVEMBER 2025 416
TABLE 497 OXFORD NANOPORE TECHNOLOGIES PLC.: DEALS,
JANUARY 2022–NOVEMBER 2025 416
TABLE 498 PROMEGA CORPORATION: COMPANY OVERVIEW 417
TABLE 499 PROMEGA CORPORATION: PRODUCTS OFFERED 418
TABLE 500 WATERS CORPORATION: COMPANY OVERVIEW 419
TABLE 501 WATERS CORPORATION: PRODUCTS OFFERED 421
TABLE 502 WATERS CORPORATION: PRODUCT LAUNCHES, JANUARY 2022–NOVEMBER 2025 422
TABLE 503 WATERS CORPORATION: DEALS, JANUARY 2022–NOVEMBER 2025 422
TABLE 504 SARTORIUS AG: COMPANY OVERVIEW 423
TABLE 505 SARTORIUS AG: PRODUCTS OFFERED 425
TABLE 506 SARTORIUS AG: DEALS, JANUARY 2022–NOVEMBER 2025 426
TABLE 507 BD: COMPANY OVERVIEW 427
TABLE 508 BD: PRODUCTS OFFERED 428
TABLE 509 BD: PRODUCT LAUNCHES, JANUARY 2022–NOVEMBER 2025 429
TABLE 510 BD: DEALS, JANUARY 2022–NOVEMBER 2025 430
TABLE 511 EPPENDORF SE: COMPANY OVERVIEW 431
TABLE 512 EPPENDORF SE: PRODUCTS OFFERED 433
TABLE 513 EPPENDORF SE: DEALS, JANUARY 2022–NOVEMBER 2025 434
TABLE 514 SHIMADZU CORPORATION: COMPANY OVERVIEW 435
TABLE 515 SHIMADZU CORPORATION: PRODUCTS OFFERED 436
TABLE 516 AURORA BIOMED INC.: COMPANY OVERVIEW 438
TABLE 517 AURORA BIOMED INC.: PRODUCTS OFFERED 438
TABLE 518 STANDARD BIOTOOLS: COMPANY OVERVIEW 439
TABLE 519 STANDARD BIOTOOLS: PRODUCTS OFFERED 440
TABLE 520 JEOL LTD.: COMPANY OVERVIEW 441
TABLE 521 JEOL LTD.: PRODUCTS OFFERED 443
TABLE 522 GILSON INCORPORATED: COMPANY OVERVIEW 444
TABLE 523 GILSON INCORPORATED: PRODUCTS OFFERED 444
TABLE 524 BIOMÉRIEUX: COMPANY OVERVIEW 445
TABLE 525 BIOMÉRIEUX: PRODUCTS OFFERED 446
TABLE 526 GREINER AG: COMPANY OVERVIEW 447
TABLE 527 GREINER AG: PRODUCTS OFFERED 448
TABLE 528 BGI GROUP: COMPANY OVERVIEW 449
TABLE 529 BGI GROUP: PRODUCTS OFFERED 449
TABLE 530 PORVAIR: COMPANY OVERVIEW 451
TABLE 531 PORVAIR: PRODUCTS OFFERED 452
TABLE 532 POLARIS GENOMICS: COMPANY OVERVIEW 453
TABLE 533 BICO: COMPANY OVERVIEW 454
TABLE 534 CREATIVE BIOARRAY: COMPANY OVERVIEW 455
TABLE 535 SPHERE BIO: COMPANY OVERVIEW 455
TABLE 536 GENSCRIPT: COMPANY OVERVIEW 456
TABLE 537 SCHRÖDINGER, INC.: COMPANY OVERVIEW 457
TABLE 538 LECO CORPORATION: COMPANY OVERVIEW 458
TABLE 539 TRANSGEN BIOTECH CO., LTD: COMPANY OVERVIEW 459
TABLE 540 BMG LABTECH: COMPANY OVERVIEW 460
TABLE 541 NANOTEMPER TECHNOLOGIES: COMPANY OVERVIEW 461
TABLE 542 MGI TECH CO., LTD.: COMPANY OVERVIEW 462
TABLE 543 ARACELI BIOSCIENCES: COMPANY OVERVIEW 463
TABLE 544 ANALYTIK JENA GMBH+CO. KG: COMPANY OVERVIEW 464
TABLE 545 BIOSOLVEIT GMBH: COMPANY OVERVIEW 465
TABLE 546 EVOSEP: COMPANY OVERVIEW 466
TABLE 547 IMPACT ANALYSIS OF SUPPLY AND DEMAND-SIDE FACTORS 478
TABLE 548 RISK ASSESSMENT 480

LIST OF FIGURES

FIGURE 1 DRUG DISCOVERY TECHNOLOGIES MARKET SEGMENTATION
AND REGIONS CONSIDERED 43
FIGURE 2 DRUG DISCOVERY TECHNOLOGIES MARKET: YEARS CONSIDERED 44
FIGURE 3 MARKET SCENARIO 47
FIGURE 4 GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET, 2023–2030 48
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN DRUG DISCOVERY TECHNOLOGIES MARKET, 2022–2025 48
FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF DRUG DISCOVERY
TECHNOLOGIES MARKET 49
FIGURE 7 HIGH-GROWTH SEGMENTS IN DRUG DISCOVERY TECHNOLOGIES MARKET,
2025–2030 50
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN DRUG DISCOVERY TECHNOLOGIES MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 51
FIGURE 9 REAGENTS & CONSUMABLES SEGMENT AND US LED NORTH AMERICAN MARKET IN 2024 53
FIGURE 10 ASIA PACIFIC IS LIKELY TO BE FASTEST-GROWING MARKET IN DRUG DISCOVERY TECHNOLOGIES MARKET DURING FORECAST PERIOD 54
FIGURE 11 REAGENTS & CONSUMABLES TO DOMINATE MARKET DURING FORECAST PERIOD 55
FIGURE 12 DRUG DISCOVERY TECHNOLOGIES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 56
FIGURE 13 DRUG DISCOVERY TECHNOLOGIES MARKET: PORTER’S FIVE FORCES ANALYSIS 65
FIGURE 14 GROWTH OF GLOBAL GDP FROM 2020 TO 2024, WITH FORECASTS UNTIL 2030 67
FIGURE 15 DRUG DISCOVERY TECHNOLOGIES MARKET: VALUE CHAIN ANALYSIS 68
FIGURE 16 DRUG DISCOVERY TECHNOLOGIES MARKET: ECOSYSTEM ANALYSIS 70
FIGURE 17 AVERAGE SELLING PRICE OF INSTRUMENTS, BY KEY PLAYER, 2024 (USD) 72
FIGURE 18 AVERAGE SELLING PRICE OF CONSUMABLES, BY KEY PLAYER, 2024 (USD) 73
FIGURE 19 AVERAGE SELLING PRICE OF INSTRUMENTS, BY REGION, 2024 (USD MILLION) 74
FIGURE 20 AVERAGE SELLING PRICE OF CONSUMABLES, BY REGION, 2024 (USD MILLION) 75
FIGURE 21 DRUG DISCOVERY TECHNOLOGIES MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 80
FIGURE 22 DRUG DISCOVERY TECHNOLOGIES MARKET: INVESTMENT AND FUNDING SCENARIO, 2022–2025 (USD MILLION) 81
FIGURE 23 PATENT APPLICATIONS IN DRUG DISCOVERY TECHNOLOGIES MARKET,
JANUARY 2014–DECEMBER 2024 92
FIGURE 24 IMPACT OF AI/GEN AI ON DRUG DISCOVERY TECHNOLOGIES MARKET 95
FIGURE 25 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT 107
FIGURE 26 KEY BUYING CRITERIA, BY END USER 108
FIGURE 27 NORTH AMERICA: DRUG DISCOVERY TECHNOLOGIES MARKET SNAPSHOT 226
FIGURE 28 ASIA PACIFIC: DRUG DISCOVERY TECHNOLOGIES MARKET SNAPSHOT 262
FIGURE 29 REVENUE ANALYSIS OF KEY PLAYERS, 2020–2024 329
FIGURE 30 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024 330
FIGURE 31 DRUG DISCOVERY TECHNOLOGIES MARKET: BRAND/PRODUCT COMPARISON 332
FIGURE 32 DRUG DISCOVERY TECHNOLOGIES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 335
FIGURE 33 DRUG DISCOVERY TECHNOLOGIES MARKET: COMPANY FOOTPRINT 336
FIGURE 34 DRUG DISCOVERY TECHNOLOGIES MARKET:
COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 342
FIGURE 35 EV/EBITDA OF KEY VENDORS 345
FIGURE 36 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA
OF KEY VENDORS 345
FIGURE 37 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024) 350
FIGURE 38 MERCK KGAA: COMPANY SNAPSHOT (2024) 357
FIGURE 39 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2024) 361
FIGURE 40 REVVITY: COMPANY SNAPSHOT (2024) 366
FIGURE 41 ILLUMINA, INC.: COMPANY SNAPSHOT (2024) 371
FIGURE 42 DANAHER CORPORATION: COMPANY SNAPSHOT (2024) 376
FIGURE 43 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2024) 383
FIGURE 44 BRUKER: COMPANY SNAPSHOT (2024) 387
FIGURE 45 QIAGEN: COMPANY SNAPSHOT (2024) 391
FIGURE 46 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2024) 395
FIGURE 47 TECAN TRADING AG: COMPANY SNAPSHOT (2024) 399
FIGURE 48 TAKARA BIO INC.: COMPANY SNAPSHOT (2024) 402
FIGURE 49 CORNING INCORPORATED: COMPANY SNAPSHOT (2024) 405
FIGURE 50 PACBIO: COMPANY SNAPSHOT (2024) 410
FIGURE 51 OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY SNAPSHOT (2024) 414
FIGURE 52 WATERS CORPORATION: COMPANY SNAPSHOT (2024) 420
FIGURE 53 SARTORIUS AG: COMPANY SNAPSHOT (2024) 424
FIGURE 54 BD: COMPANY SNAPSHOT (2024) 428
FIGURE 55 EPPENDORF SE: COMPANY SNAPSHOT (2024) 432
FIGURE 56 SHIMADZU CORPORATION: COMPANY SNAPSHOT (2024) 436
FIGURE 57 STANDARD BIOTOOLS: COMPANY SNAPSHOT (2024) 440
FIGURE 58 JEOL LTD.: COMPANY SNAPSHOT 442
FIGURE 59 BIOMÉRIEUX: COMPANY SNAPSHOT (2024) 446
FIGURE 60 GREINER AG: COMPANY SNAPSHOT (2024) 448
FIGURE 61 PORVAIR: COMPANY SNAPSHOT (2024) 452
FIGURE 62 DRUG DISCOVERY TECHNOLOGIES MARKET: RESEARCH DESIGN 467
FIGURE 63 DRUG DISCOVERY TECHNOLOGIES MARKET: BREAKDOWN OF PRIMARIES 470
FIGURE 64 DRUG DISCOVERY TECHNOLOGIES MARKET: INSIGHTS FROM PRIMARIES 471
FIGURE 65 DRUG DISCOVERY TECHNOLOGIES MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH) (2024) 472
FIGURE 66 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.:
REVENUE ANALYSIS (2024) 472
FIGURE 67 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 474
FIGURE 68 DRUG DISCOVERY TECHNOLOGIES BASE NUMBER CALCULATION
(SUPPLY-SIDE ANALYSIS), 2024 475
FIGURE 69 DRUG DISCOVERY TECHNOLOGIES MARKET: CAGR PROJECTIONS 476
FIGURE 70 DRUG DISCOVERY TECHNOLOGIES MARKET: DATA TRIANGULATION 477
 

---

---